Gastric cancer - metastatic (stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction

The PBS subsidises trastuzumab for patients with metastatic (stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.

Patient eligibility

Treatment with trastuzumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 100 arrangements for the Efficient Funding of Chemotherapy for a patient with metastatic (stage IV) human epidermal growth factor receptor 2 (HER2) positive adenocarcinoma of the stomach or gastro-oesophageal junction.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing trastuzumab.

Section 100 arrangements

This item is only available for day admitted patients, non-admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

This item is not PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Application

Initial application

Make all initial applications for authority approval to prescribe trastuzumab for the treatment of metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction in writing and:

All applications must include the completed:

Continuing treatment

To make continuing applications for treatment with trastuzumab call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 5 July 2018